RxDoctor Payments Data

Doron Schneider, MD

Internal Medicine · Abington, PANPI 1891791828

Payments from drug & device makers

$127,260in general payments, 2019–2025

Across 156 payments — averaging $815.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$82K
  • Novo Nordisk AS$31K
  • Lilly USA, LLC$6K
  • Insulet Corporation$5K
  • Eli Lilly$3K
  • AbbVie$175
  • plus $100 from 4 others

What the payments were for

  • Consulting fees$51,51340%
  • Speaking & faculty fees$56,54444%
  • Travel & lodging$17,37514%
  • Food & beverage$1,8281%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$127,260 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$20,847
Medicare patients
88
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$36,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,780
SynthroidLevothyroxine Sodium23$1,942
Valsartan17$1,095
Atorvastatin Calcium84$905
Rosuvastatin Calcium41$896
Metoprolol Succinate45$707
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide21$666
Losartan Potassium41$559
Levothyroxine Sodium40$487
Escitalopram Oxalate19$337
Lovastatin12$291
Potassium Chloride13$277
Amlodipine Besylate55$274
Simvastatin28$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$81,698$36,16219 claims
AbbVieSynthroid$175$1,94223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →